Albumin Nano-Encapsulation of Piceatannol Enhances Its Anticancer Potential in Colon Cancer Via Downregulation of Nuclear p65 and HIF-1α

A.a. Aljabali, Hamid Bakshi, L. Hakkim, A. Haggag, M. Al-batanyeh, S. Al Zoubi, Bahaa Al-trad, Mohamad Nasef, Saurabh Satija, Prina Mehta, Kavita Pabreja, Vijay Mishra, Mohammed Khan, Abobaker, Azzouz, Harish Dureja, Pabari, Dardouri, Prashant Kesharwani, Shalabh Gupta & 11 others Dhar Shukla, Prasher, B. Charbe, S Negi, N. Kapoor, Dinesh Kumar Chellappan, Mateus Webba da Silva, John Thompson, Harminder S Dua, Paul McCarron, Murtaza Tambuwala

Research output: Contribution to journalArticle

Abstract

Piceatannol (PIC) is known to have anticancer activity, which has been attributed to its ability to block the proliferation of cancer cells via suppression of the NF-kB signaling pathway. However, its effect on hypoxia-inducible factor (HIF) is not well known in cancer. In this study, PIC was loaded into bovine serum albumin (BSA) by desolvation method as PIC–BSA nanoparticles (NPs). These PIC–BSA nanoparticles were assessed for in vitro cytotoxicity, migration, invasion, and colony formation studies and levels of p65 and HIF-1α. Our results indicate that PIC–BSA NPs were more effective in downregulating the expression of nuclear p65 and HIF-1α in colon cancer cells as compared to free PIC. We also observed a significant reduction in inflammation induced by chemical colitis in mice by PIC–BSA NPs. Furthermore, a significant reduction in tumor size and number of colon tumors was also observed in the murine model of colitis-associated colorectal cancer, when treated with PIC–BSA NPs as compared to free PIC. The overall results indicate that PIC, when formulated as PIC–BSA NPs, enhances its therapeutic potential. Our work could prompt further research in using natural anticancer agents as nanoparticels with possible human clinical trails. This could lead to the development of a new line of safe and effective therapeutics for cancer patients.
LanguageEnglish
Pages113
JournalCancers
Volume12
Issue number1
DOIs
Publication statusPublished - 1 Jan 2020

Fingerprint

Colonic Neoplasms
Albumins
Down-Regulation
Bovine Serum Albumin
Nanoparticles
Colitis
Neoplasms
3,3',4,5'-tetrahydroxystilbene
Hypoxia
NF-kappa B
Antineoplastic Agents
Colorectal Neoplasms
Colon
Cell Proliferation
Inflammation
Therapeutics

Keywords

  • piceatannol
  • colon cancer
  • albumin nanoparticles
  • nuclear P65
  • HIF-1α

Cite this

A.a. Aljabali, ; Bakshi, Hamid ; L. Hakkim ; A. Haggag ; M. Al-batanyeh ; S. Al Zoubi ; Al-trad, Bahaa ; Nasef, Mohamad ; Satija, Saurabh ; Mehta, Prina ; Pabreja, Kavita ; Mishra, Vijay ; Khan, Mohammed ; Abobaker ; Azzouz ; Dureja, Harish ; Pabari ; Dardouri ; Kesharwani, Prashant ; Gupta, Shalabh ; Dhar Shukla ; Prasher ; B. Charbe ; Negi, S ; N. Kapoor ; Chellappan, Dinesh Kumar ; Webba da Silva, Mateus ; Thompson, John ; Dua, Harminder S ; McCarron, Paul ; Tambuwala, Murtaza. / Albumin Nano-Encapsulation of Piceatannol Enhances Its Anticancer Potential in Colon Cancer Via Downregulation of Nuclear p65 and HIF-1α. In: Cancers. 2020 ; Vol. 12, No. 1. pp. 113.
@article{89dc08fef4154705bff8d8564ed81306,
title = "Albumin Nano-Encapsulation of Piceatannol Enhances Its Anticancer Potential in Colon Cancer Via Downregulation of Nuclear p65 and HIF-1α",
abstract = "Piceatannol (PIC) is known to have anticancer activity, which has been attributed to its ability to block the proliferation of cancer cells via suppression of the NF-kB signaling pathway. However, its effect on hypoxia-inducible factor (HIF) is not well known in cancer. In this study, PIC was loaded into bovine serum albumin (BSA) by desolvation method as PIC–BSA nanoparticles (NPs). These PIC–BSA nanoparticles were assessed for in vitro cytotoxicity, migration, invasion, and colony formation studies and levels of p65 and HIF-1α. Our results indicate that PIC–BSA NPs were more effective in downregulating the expression of nuclear p65 and HIF-1α in colon cancer cells as compared to free PIC. We also observed a significant reduction in inflammation induced by chemical colitis in mice by PIC–BSA NPs. Furthermore, a significant reduction in tumor size and number of colon tumors was also observed in the murine model of colitis-associated colorectal cancer, when treated with PIC–BSA NPs as compared to free PIC. The overall results indicate that PIC, when formulated as PIC–BSA NPs, enhances its therapeutic potential. Our work could prompt further research in using natural anticancer agents as nanoparticels with possible human clinical trails. This could lead to the development of a new line of safe and effective therapeutics for cancer patients.",
keywords = "piceatannol, colon cancer, albumin nanoparticles, nuclear P65, HIF-1α",
author = "{A.a. Aljabali} and Hamid Bakshi and {L. Hakkim} and {A. Haggag} and {M. Al-batanyeh} and {S. Al Zoubi} and Bahaa Al-trad and Mohamad Nasef and Saurabh Satija and Prina Mehta and Kavita Pabreja and Vijay Mishra and Mohammed Khan and Abobaker and Azzouz and Harish Dureja and Pabari and Dardouri and Prashant Kesharwani and Shalabh Gupta and {Dhar Shukla} and Prasher and {B. Charbe} and S Negi and {N. Kapoor} and Chellappan, {Dinesh Kumar} and {Webba da Silva}, Mateus and John Thompson and Dua, {Harminder S} and Paul McCarron and Murtaza Tambuwala",
note = "Accepted date is listed on the uploaded manuscript",
year = "2020",
month = "1",
day = "1",
doi = "10.3390/cancers12010113",
language = "English",
volume = "12",
pages = "113",
journal = "Cancers",
issn = "2072-6694",
publisher = "MDPI",
number = "1",

}

A.a. Aljabali, , Bakshi, H, L. Hakkim, A. Haggag, M. Al-batanyeh, S. Al Zoubi, Al-trad, B, Nasef, M, Satija, S, Mehta, P, Pabreja, K, Mishra, V, Khan, M, Abobaker, Azzouz, Dureja, H, Pabari, Dardouri, Kesharwani, P, Gupta, S, Dhar Shukla, Prasher, B. Charbe, Negi, S, N. Kapoor, Chellappan, DK, Webba da Silva, M, Thompson, J, Dua, HS, McCarron, P & Tambuwala, M 2020, 'Albumin Nano-Encapsulation of Piceatannol Enhances Its Anticancer Potential in Colon Cancer Via Downregulation of Nuclear p65 and HIF-1α', Cancers, vol. 12, no. 1, pp. 113. https://doi.org/10.3390/cancers12010113

Albumin Nano-Encapsulation of Piceatannol Enhances Its Anticancer Potential in Colon Cancer Via Downregulation of Nuclear p65 and HIF-1α. / A.a. Aljabali, ; Bakshi, Hamid; L. Hakkim; A. Haggag; M. Al-batanyeh; S. Al Zoubi; Al-trad, Bahaa; Nasef, Mohamad; Satija, Saurabh; Mehta, Prina; Pabreja, Kavita; Mishra, Vijay; Khan, Mohammed; Abobaker; Azzouz; Dureja, Harish; Pabari; Dardouri; Kesharwani, Prashant; Gupta, Shalabh; Dhar Shukla; Prasher; B. Charbe; Negi, S; N. Kapoor; Chellappan, Dinesh Kumar; Webba da Silva, Mateus; Thompson, John; Dua, Harminder S; McCarron, Paul; Tambuwala, Murtaza.

In: Cancers, Vol. 12, No. 1, 01.01.2020, p. 113.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Albumin Nano-Encapsulation of Piceatannol Enhances Its Anticancer Potential in Colon Cancer Via Downregulation of Nuclear p65 and HIF-1α

AU - A.a. Aljabali, null

AU - Bakshi, Hamid

AU - L. Hakkim, null

AU - A. Haggag, null

AU - M. Al-batanyeh, null

AU - S. Al Zoubi, null

AU - Al-trad, Bahaa

AU - Nasef, Mohamad

AU - Satija, Saurabh

AU - Mehta, Prina

AU - Pabreja, Kavita

AU - Mishra, Vijay

AU - Khan, Mohammed

AU - Abobaker, null

AU - Azzouz, null

AU - Dureja, Harish

AU - Pabari, null

AU - Dardouri, null

AU - Kesharwani, Prashant

AU - Gupta, Shalabh

AU - Dhar Shukla, null

AU - Prasher, null

AU - B. Charbe, null

AU - Negi, S

AU - N. Kapoor, null

AU - Chellappan, Dinesh Kumar

AU - Webba da Silva, Mateus

AU - Thompson, John

AU - Dua, Harminder S

AU - McCarron, Paul

AU - Tambuwala, Murtaza

N1 - Accepted date is listed on the uploaded manuscript

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Piceatannol (PIC) is known to have anticancer activity, which has been attributed to its ability to block the proliferation of cancer cells via suppression of the NF-kB signaling pathway. However, its effect on hypoxia-inducible factor (HIF) is not well known in cancer. In this study, PIC was loaded into bovine serum albumin (BSA) by desolvation method as PIC–BSA nanoparticles (NPs). These PIC–BSA nanoparticles were assessed for in vitro cytotoxicity, migration, invasion, and colony formation studies and levels of p65 and HIF-1α. Our results indicate that PIC–BSA NPs were more effective in downregulating the expression of nuclear p65 and HIF-1α in colon cancer cells as compared to free PIC. We also observed a significant reduction in inflammation induced by chemical colitis in mice by PIC–BSA NPs. Furthermore, a significant reduction in tumor size and number of colon tumors was also observed in the murine model of colitis-associated colorectal cancer, when treated with PIC–BSA NPs as compared to free PIC. The overall results indicate that PIC, when formulated as PIC–BSA NPs, enhances its therapeutic potential. Our work could prompt further research in using natural anticancer agents as nanoparticels with possible human clinical trails. This could lead to the development of a new line of safe and effective therapeutics for cancer patients.

AB - Piceatannol (PIC) is known to have anticancer activity, which has been attributed to its ability to block the proliferation of cancer cells via suppression of the NF-kB signaling pathway. However, its effect on hypoxia-inducible factor (HIF) is not well known in cancer. In this study, PIC was loaded into bovine serum albumin (BSA) by desolvation method as PIC–BSA nanoparticles (NPs). These PIC–BSA nanoparticles were assessed for in vitro cytotoxicity, migration, invasion, and colony formation studies and levels of p65 and HIF-1α. Our results indicate that PIC–BSA NPs were more effective in downregulating the expression of nuclear p65 and HIF-1α in colon cancer cells as compared to free PIC. We also observed a significant reduction in inflammation induced by chemical colitis in mice by PIC–BSA NPs. Furthermore, a significant reduction in tumor size and number of colon tumors was also observed in the murine model of colitis-associated colorectal cancer, when treated with PIC–BSA NPs as compared to free PIC. The overall results indicate that PIC, when formulated as PIC–BSA NPs, enhances its therapeutic potential. Our work could prompt further research in using natural anticancer agents as nanoparticels with possible human clinical trails. This could lead to the development of a new line of safe and effective therapeutics for cancer patients.

KW - piceatannol

KW - colon cancer

KW - albumin nanoparticles

KW - nuclear P65

KW - HIF-1α

UR - https://www.mdpi.com/2072-6694/12/1/113

UR - https://www.ncbi.nlm.nih.gov/pubmed/?term=31906321

U2 - 10.3390/cancers12010113

DO - 10.3390/cancers12010113

M3 - Article

VL - 12

SP - 113

JO - Cancers

T2 - Cancers

JF - Cancers

SN - 2072-6694

IS - 1

ER -